ABSTRACT. The goal of the study was the determination of the relative roles of the placenta and the fetus in causing low serum estriol (E3) levels in women bearing fetuses with intrauterine growth retardation (IUGR). Umbilical venous levels of E3 and dehydroepiandrosterone sulfate (DHAS) were measured in 31 samples from fetuses with IUGR, 21 of whom were vaginally delivered and 10 who were delivered by cesarean section. In addition, estrone (El) and estradiol (E2) were measured in 11 of the samples. The results were compared with 11 samples from cesarean section delivered control term infants and 54 samples from vaginally delivered control infants. The vaginally delivered IUGR group had a significantly lower mean umbilical venous DHAS level than did their control group (2128 + 158 ng/ml S E M versus 2645 + 130, p < 0.05). Both the vaginally delivered and cesarean section delivered IUGR infants had umbilical venous E3 levels significantly lower than in their control groups (70 2 1 0 ng/ml S E M versus 144 + 10, p < 0.001, and 46 2 1 1 ng/ml S E M versus 136 2 23, p < .01, respectively). Umbilical venous El and EZ levels were not different from the control values. El, EZ, E3, and DHAS were measured in eight maternal venous samples obtained from mothers bearing fetuses with IUGR. In comparison with 11 control mothes, only E3 was significantly different (10.7 + 3.0 ng/ml S E M in mothers with IUGR fetuses versus 25.0 + 4.9 in control mothersp < 0.01). The study provides evidence for reduced DHAS secretion in one group of the fetuses with IUGR, and no evidence for decreased placental conversion of DEIAS to the estrogens El and EZ. The significantly low E3 values in both umbilical and maternal samples are postulated to result not only from the reduced fetal adrenal DHAS secretion, but also underactive 16a-hydroxylase activity in fetal liver or low efficiency of 16a-OH-DHAS, relative to DHAS, as a substrate for placental conversion to an estrogen. (Pediatr Res 20: 166-168, 1986) Abbreviations IUGR, intrauterine growth retardation DHAS, dehydroepiandrosterone sulfate E,, estrone E2, estradiol E3, estriol Women bearing fetuses with IUGR frequently have low serum E3 levels in late gestation (1, 2). One origin of the low E3 production in these pregnancies may be reduced secretion of fetal adrenal cortex-derived neutral steroid precursors of estriol synthesis in the placenta (3). However, there is evidence that placental conversion of the neutral precursors to estrogen may be low in association with a fetus with IUGR (4). In order to investigate the relative importance of these two possible causes of low Ej production, umbilical venous, and maternal venous neutral steroid and estrogen levels were assessed in a series of pregnancies in which the fetus had IUGR.
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MATERIALS AND METHODS
Patients. All pregnant women studied in this investigation were hospitalized in the Oregon Health Sciences University Hospital. Fetuses with IUGR were diagnosed when their birth weights were more than 2 SD below the mean for gestational age, as defined by the Babson and Benda (5) fetal growth curves. No fetuses with congenital infections or major anomalies were included in the study.
The maternal diagnoses included pregnancy-induced hypertension, chronic hypertension, chronic abruptio placenta, placenta previa, bifid uterus, and chronic leakage of amniotic fluid. A number of cases had fibrotic placentas with no obvious associated maternal pathologic process. The number of patients in each subcategory were insufficient to allow comparisons of patients in the subgroups.
Umbilical venous blood samples were obtained from 3 1 fetuses with IUGR, 21 of whom were delivered vaginally and 10 by cesarean section. All but two were 37 wk gestation or older. DHAS and unconjugated El were determined in all samples, and in 1 1 samples, El and E2 17P were measured in addition. Six of these I 1 samples were from vaginally delivered infants and five from infants delivered by cesarean section. Maternal blood samples were collected a few hours prepartum from eight of the mothers of the latter group of I I infants for El, E2, E3, and DHAS concentration measurements. All of these eight pregnancies were 38 wk gestation or more.
Control samples for steroids in umbilical venous serum and maternal venous serum from cesarean section deliveries were obtained from 1 1 women at term with uncomplicated pregnancies. Each had a weight gain of 20-35 Ib, normal blood pressure, did not smoke, and took no medications chronically. Each woman was delivered via elective cesarean section prior to labor. steroid. The method for unconjugated E, assay was described by Barnhart et al. (6) , and cortisol was measured as described by Barnhart et al. (6) .
Unconjugated E, was extracted from serum samples with benzene. An antiestrone-6-(CMO) bovine serum albumin antibody E-00 1 from Steranti Research Ltd. was used for the radioimmunoassay system in a 1:1000 dilution, and dextran-coated charcoal was used for bound and free steroid separation. The cross-reactivities of the El antibody were (El-100%): Eq 17P-0.1 %, E,-0.0 1 %, DHA-0.0 I %, progesterone-<0.0 1 %. Intraassay variability was 2.1 % and interassay variability was 13.2%.
Unconjugated Eq was assayed in serum samples extracted with benzene. A rabbit anti-E2 antibody (R-14) provided by Dr. L. Don Keith, Veteran's Administration Hospital, Portland, OR was used at a 1:400,000 dilution, and dextran-coated charcoal was used for bound and free steroid separation. The crossreactivities of the Eq antibody were (E2-100%): El-2.0%, Ej-0.2%, DHA-0.0 1 %, testosterone-0.06%, cortisol-0.03%. Intraassay variability was 7.0% and interassay variability was 13.0%.
The significance of differences between means was determined by use of Student's t test.
RESULTS
Umbilical venous serum levels of DHAS and E3 in 2 1 samples from vaginally delivered infants with IUGR and 10 from infants with IUGR delivered by cesarean section are listed in Table 1 . In addition, E, and Eq were assayed in six of the vaginally delivered and five of those delivered by cesarean section ( Table  1) . Values of El, El, E,, and DHAS in I I control umbilical venous samples from infants delivered by cesarean section and values of E3 and DHAS in 54 samples from vaginally delivered control infants are included in Table 1 Table 2 shows the maternal venous levels of El, E,, E,, and DHAS in mothers of eight of the I1 fetuses with IUGR listed in Table 1 who had the same serum steroids assayed. The steroid values in control prepartum samples from the 1 1 control women Significance of differences between control and IUGR groups; 1-11 < 0.00 1 : $11 < 0.05: $11 < 0.0 1. 
DISCUSSION
Adrenocortical function of growth retarded fetuses has long been known to be potentially abnormal. Naeye (8) described the adrenal cortex of the IUGR newborn infant as relatively smalle:r than other organs, with the fetal zone even more retarded than the permanent zone. In a study by Reynolds and Mirkin (3), newborns with IUGR were shown to have reduced urinary excretion of 16a-hydroxy DHAS, a metabolic product of DHAS which is secreted mainly by the fetal zone of the adrenal cortex. However, these infants had normal urinary levels of the metabolic products of cortisol, 6P-hydroxy cortisol and tetrahydrocortisone, which is secreted mainly by the permanent zone. In another group of IUGR newborns 36 wk gestation or greateir studied on the 1st day of life, the serum DHAS levels were found to be significantly lower than in normally grown newborn infants of the same gestational age (7) .
Further evidence of disturbed adrenocortical function in the IUGR group comes from reports that the mean maternal serum E3 levels (1,2) and maternal urinary excretion of E, (9) are lower than expected for the duration of gestation and fetal size in women bearing a fetus with IUGR. As more than 90% of E3 in a woman in late pregnancy is derived from fetal adrenal-derived neutral steroid precursors, principally DHAS (lo), diminished levels of maternal E3 generally are considered to indicate abnormally low fetal adrenocortical steroid secretion.
In the sequence of biosynthetic steps leading from DHAS to E,, the DHAS first undergoes 16a-hydroxylation in the fetal liver, then in the placenta undergoes conversion to E,. The placental enzymes necessary for the biosynthesis of E3 from 1601.-OH-DHAS include sulfatase, 3P-hydroxysteroid dehydrogenase, and aromatizing enzymes. Potentially, a diminished activity of any one of these enzymatic steps could lead to low E, productior~ in the fetoplacental unit in the face of normal adrenal DHAS; secretion. Hepatic 16a-hydroxylase has been reported to be low, in association with normal fetal DHAS production, in only one instance (1 1). The fetus had cirrhosis, and the mother had increased El and E2 excretions, and abnormally low E, excretion.
In normal pregnancies, the placental enzymes are considered to have a large capacity, and not to be rate limiting in estrogen biosynthesis (12) . Their activities show no correlation with urinary estrogen levels over a wide range of estrogen excretions (12) .
In abnormal placentas, steroid metabolizing enzymes assessed in vitro have been variously reported to be low (4, 13) or increased (14) in mothers with toxemia, or in mothers bearing IUGR. fetuses. There are recent studies indicating that in vivo placental conversion of DHAS to El and E2 is depressed in women with fetuses showing IUGR (1 5-17) . In addition, diminished clearance of DHAS by these patients is shown by a prolonged halflife of administered DHAS (18, 19) . The placental clearance of DHAS by conversion to E2 appears to be a direct reflection of 168 REYNOLDS ET AL.
uteroplacental blood flow (20) , and the reduced clearance in women bearing fetuses with IUGR is most probably related to the high frequency of vascular pathology (21) and the reduced blood flow (22) found in the placentas of these pregnancies. Thus, in pregnancies where uteroplacental blood flow is reduced as part of a pathologic process, the placental role in estrogen production may be limiting in proportion to the decrease in placental blood perfusion, as well as limiting because of the pathologic damage to the placenta itself.
The results of the present study indicate that in the IUGR groups studied there was some, although inconsistent, evidence that fetal adrenocortical function was disturbed. There were significantly lower umbilical venous DHAS levels in the vaginally delivered IUGR infants than in the normally grown control group of vaginally delivered infants, suggesting a reduced fetal adrenocortical secretion of DHAS in the subgroup with IUGR. The mean umbilical serum DHAS level in the IUGR subgroup delivered by cesarean section was somewhat lower than in their control group of normally grown cesarean section delivered infants, but the difference did not reach the level of significance.
The reductions in umbilical venous E3 levels in the IUGR groups, as compared to the control groups, were more consistent and were of greater magnitude than were the reductions in DHAS levels. This difference in the patterns of DHAS and E3 reductions suggested that there was not only a fetal factor, but also a placental factor in the causation of the low umbilical venous and maternal venous El levels. To investigate the role of a general placental aromatizing enzyme underactivity as a cause of the low umbilical venous E3 levels, umbilical venous El and E2 levels were measured in a subset of 11 cord blood samples, and El, EZ, El, and DHAS were measured in maternal venous samples obtained from the mothers of eight of these 11 infants. The umbilical venous El and E2 levels were in the normal range. The maternal E3 levels were found to be significantly low. The maternal venous El and E2 levels were lower and the DHAS levels were higher in the IUGR group, but the differences from the control group did not reach significant levels. However, the differences suggest an underactivity of placental aromatizing enzymes in mothers of IUGR fetuses.
The normal umbilical venous El and E, levels would indicate that there was not a general reduction of the placental enzymes responsible for conversion of neutrai fetal steroids to estrogens. It is possible that the neutral steroid precursor of El, 16a-OH-DHAS, is a less efficient substrate for the placental enzymes than is DHAS, the neutral steroid precursor of El and E2. There is no in vifro evidence for this possibility, although it has been suggested by in vivo studies in women in late pregnancy (23) .
Another possible explanation for the discrepancy in umbilical DHAS and E3 levels is a reduced fetal hepatic 16a-hydroxylase activity, as well as reduced DHAS secretion, in fetuses with IUGR. Nothing is known about the control of this enzyme in the fetus. The activity of this enzyme in women in late pregnancy is increased, probably as a result of the high circulating estrogen levels (24) . However, in the human fetus, placental sulfatase deficiency, leading to very low circulating fetal E, and E2 levels, is not associated with low hepatic l6a-hydroxylase activities (25) . In addition, the fetuses we studied had normal serum El and E2 levels. Thus, there is no evident hormonal basis for reduced fetal hepatic 16~-hydroxylase activity. However, the liver in fetuses with IUGR is known to be particularly retarded in its growth (8) , and certain hepatic enzymes, e.g. the gluconeogenic system, may be underactive in IUGR (26, 27) . Definitive proof for the hypothesis that hepatic 16a-hydroxylase activity is reduced in the IUGR group is not available and would require the demonstration of low fetal circulating 16~-OH-DHAS levels and low E3 levels, in relation to the serum DHAS concentrations.
